我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
2
0 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
2011
已完成
100.0%
暂无批准数据
- Essex-based Thetis Pharmaceuticals has received $9 million from the Helmsley Charitable Trust to advance TP-317, an innovative oral therapy for inflammatory bowel disease. - TP-317, a naturally occurring lipid, aims to reduce inflammation and repair intestinal lining without compromising immune function, offering advantages over current injection-based treatments. - The funding will support a Phase 1b trial of TP-317 in ulcerative colitis patients, building on previous investments totaling over $14 million from the Helmsley Trust.
